Author’s response to reviews

Title: Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis

Authors:

Eric Simpson (simpsonE@ohsu.edu)
Laurent Eckert (Laurent.Eckert@sanofi.com)
Abhijit Gadkari (abhijit.gadkari@regeneron.com)
Usha Mallya (Usha.Mallya@sanofi.com)
Min Yang (Min.Yang@analysisgroup.com)
Lauren Nelson (lnelson@rti.org)
Michelle Brown (tmbrown@rti.org)
Matt Reaney (Matthew.d.reaney@gmail.com)
Puneet Mahajan (Sunny.Mahajan@sanofi.com)
Isabelle Guillemin (Isabelle.Guillemin@sanofi.com)
Mark Boguniewicz (BoguniewiczM@njhealth.org)
David Pariser (dpariser@pariserderm.com)

Version: 4 Date: 04 Oct 2019

Author’s response to reviews:

September 26, 2019

Nooshin Bagherani, Tehran University of Medical Sciences, Tehran, Iran
Associate Editor, BMC Dermatology
Dear Dr. Bagherani,

On behalf of my coauthors, I would like to thank you and the reviewers for the final review of our manuscript entitled “Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis” (BDER-D-19-00040R1), following resubmission of a version in which a number of peer-review queries were addressed

Below are point-by-point responses addressing the final editorial comments.

We hope that the revised manuscript is now acceptable for publication in BMC Dermatology.

Sincerely,

Laurent Eckert

1. Please note that change in authorship forms have been signed by each author, and we have submitted the document of collated forms to support the present resubmission.

2. Please note that the ADCT© is protected by copyright with all rights reserved to Sanofi and its development partners: https://patient-questionnaires.sanofi.com/questionnaires/adct-atopic-dermatitis-control-communication-tool). The tool is internationally distributed by Mapi Research Trust. Any user who wishes to use and/or translate the Sanofi PRO questionnaires must complete a User Agreement with Mapi Research Trust.

The following details of the copyright have been added to the methods section: The ADCT© is protected by copyright with all rights reserved to Sanofi, and its development partners.

3. Regarding ethics approval, the related text has now been placed in the specific section. Furthermore, the wording addresses the fact that approval was for the real-world study only:

Patients must have consented online to participate in the real-world study prior to proceeding to completing the baseline questions through a secure online portal. The survey was performed in accordance with the Helsinki Declaration of 1964 and its later amendments and received a full review approval by the New England Independent Review Board in December 2017.

4. Acknowledgements: Please note that, as requested, we have removed the funding information from the Acknowledgements section of the manuscript, and this is now only provided in the Funding section.
5. A link to the ADCT (ADCT v1; https://patient-questionnaires.sanofi.com/questionnaires/adct-atopic-dermatitis-control-communication-tool) has been included in the Background section of the manuscript (page 4, paragraph 3)

It is worth noting that by directing the reader to this web page will ensure public access to all available translations as well as the most recently validated version the ADCT. This is now a standard practice for dissemination of PRO instruments

6. Please note that the following keywords have been provided:

ADCT; atopic dermatitis control tool; symptoms; impacts; reliability; validity; responsiveness.